1. Home
  2. THRD vs BGX Comparison

THRD vs BGX Comparison

Compare THRD & BGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • THRD
  • BGX
  • Stock Information
  • Founded
  • THRD 2019
  • BGX 2010
  • Country
  • THRD United States
  • BGX United States
  • Employees
  • THRD N/A
  • BGX N/A
  • Industry
  • THRD Biotechnology: Pharmaceutical Preparations
  • BGX Trusts Except Educational Religious and Charitable
  • Sector
  • THRD Health Care
  • BGX Finance
  • Exchange
  • THRD Nasdaq
  • BGX Nasdaq
  • Market Cap
  • THRD 157.7M
  • BGX 157.8M
  • IPO Year
  • THRD 2022
  • BGX N/A
  • Fundamental
  • Price
  • THRD $3.55
  • BGX $12.32
  • Analyst Decision
  • THRD Hold
  • BGX
  • Analyst Count
  • THRD 3
  • BGX 0
  • Target Price
  • THRD $5.00
  • BGX N/A
  • AVG Volume (30 Days)
  • THRD 343.0K
  • BGX 67.9K
  • Earning Date
  • THRD 05-14-2025
  • BGX 01-01-0001
  • Dividend Yield
  • THRD N/A
  • BGX 10.34%
  • EPS Growth
  • THRD N/A
  • BGX N/A
  • EPS
  • THRD N/A
  • BGX N/A
  • Revenue
  • THRD N/A
  • BGX N/A
  • Revenue This Year
  • THRD N/A
  • BGX N/A
  • Revenue Next Year
  • THRD N/A
  • BGX N/A
  • P/E Ratio
  • THRD N/A
  • BGX N/A
  • Revenue Growth
  • THRD N/A
  • BGX N/A
  • 52 Week Low
  • THRD $3.18
  • BGX $10.69
  • 52 Week High
  • THRD $16.94
  • BGX $12.44
  • Technical
  • Relative Strength Index (RSI)
  • THRD 42.90
  • BGX 36.63
  • Support Level
  • THRD $3.34
  • BGX $12.26
  • Resistance Level
  • THRD $3.68
  • BGX $12.46
  • Average True Range (ATR)
  • THRD 0.14
  • BGX 0.09
  • MACD
  • THRD 0.07
  • BGX 0.00
  • Stochastic Oscillator
  • THRD 62.86
  • BGX 20.69

About THRD Third Harmonic Bio Inc.

Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.

About BGX Blackstone Long Short Credit Income Fund

Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It seeks to achieve its investment objectives by employing a dynamic long-short strategy in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first- and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.

Share on Social Networks: